Skip to main content
SpringerLink
Log in

Pustulöse Psoriasis

Pustular psoriasis

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Eine Reihe pustulöser Hauterkrankungen teilen klinische, pathogenetische und epidemiologische Aspekte mit der Psoriasis vulgaris, und ihre Einordung als eigene klinische Entitäten oder Unterformen der Psoriasis ist weiterhin umstritten, was sich auch in der Vielzahl ihrer Bezeichnungen widerspiegelt. Hierzu gehören die generalisierte pustulöse Psoriasis mit ihren Sonderformen, die Acrodermatitis continua suppurativa, die akute Pustulosis palmoplantaris, die Psoriasis pustulosa palmoplantaris sowie pustulöse Varianten der vorwiegend durch TNF-Blocker getriggerten paradoxen psoriasiformen Dermatitis. In diesem Beitrag werden Erkenntnisse zu Epidemiologie, klinischem Bild, Pathogenese, Genetik und Therapie dieser pustulösen Hauterkrankungen dargestellt.

Abstract

A number of pustular skin diseases share clinical, pathogenetic, and epidemiological aspects with plaque-type psoriasis, and their classification as a separate clinical entity or as a subtype of psoriasis remains controversial, which is also reflected in the multitude of their names. They include generalized pustular psoriasis with its subtypes, acrodermatitis continua suppurativa (Hallopeau), acute pustulosis palmopantaris, palmoplantar pustular psoriasis, and pustular variants of a mostly TNF-blocker triggered paradoxical psoriasiform dermatitis. In this article, the epidemiology, clinical picture, pathogenesis, genetics, and therapy of these pustular skin diseases are described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Capon F (2013) IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg? J Invest Dermatol 133:2503–2504

    Article  CAS  PubMed  Google Scholar 

  2. Korber A, Mossner R, Renner R et al (2013) Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 133(11):2634–2637

    Article  PubMed  Google Scholar 

  3. Marrakchi S, Guigue P, Renshaw BR et al (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365:620–628

    Article  CAS  PubMed  Google Scholar 

  4. Berki DM, Liu L, Choon SE et al (2015) Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis Vulgaris. J Invest Dermatol 135:2964–2970

    Article  CAS  PubMed  Google Scholar 

  5. Brenner M, Molin S, Ruebsam K, Weisenseel P, Ruzicka T, Prinz JC (2009) Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol 161:964–966

  6. Weisenseel P, Reich K (2013) Paradoxical skin reactions under therapy with TNF-alpha antagonists. Z Rheumatol 72:423–428

    Article  CAS  PubMed  Google Scholar 

  7. Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., Kalb RE (2012) Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 67:279-288 (2012)

  8. Imafuku S, Honma M, Okubo Y et al (2016) Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol : doi:/10.1111/1346-8138.13306

    Google Scholar 

  9. Saeki H, Nakagawa H, Ishii T et al (2015) Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29:1148–1155

    Article  CAS  PubMed  Google Scholar 

  10. Fujisawa T, Suzuki S, Mizutani Y et al (2015) Granulocyte and monocyte adsorption Apheresis for generalized pustular psoriasis: therapeutic outcomes in three refractory patients. Ther Apher Dial 19:336–341

    Article  PubMed  Google Scholar 

  11. Huffmeier U, Watzold M, Mohr J et al (2014) Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 170:202–204

    Article  CAS  PubMed  Google Scholar 

  12. Gao QQ, Xi MR, Yao Q (2013) Impetigo Herpetiformis during pregnancy: a case report and literature review. Dermatology 226:35–40

    Article  PubMed  Google Scholar 

  13. Sugiura K, Oiso N, Iinuma S et al (2014) IL36RN mutations underlie impetigo herpetiformis. J Invest Dermatol 134:2472–2474

    Article  CAS  PubMed  Google Scholar 

  14. Liao PB, Rubinson R, Howard R et al (2002) Annular pustular psoriasis–most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol 19:19–25

    Article  PubMed  Google Scholar 

  15. Albert A, Hein R, Ring J et al (2007) Erythema annulare centrifugum-like psoriasis cum pustulatione. Hautarzt 58:769–773

    Article  CAS  PubMed  Google Scholar 

  16. Stadler R, Orfanos CE (1981) Erythema anulare centrifugum with pustulation. Successful oral retinoid therapy. Hautarzt 32:564–566

    CAS  PubMed  Google Scholar 

  17. Vocks E, Worret WI, Ring J (2003) Erythema annulare centrifugum-type psoriasis: a particular variant of acute-eruptive psoriasis. J Eur Acad Dermatol Venereol 17:446–448

    Article  CAS  PubMed  Google Scholar 

  18. Lo SA, Brancaccio G, Puca RV et al (2012) Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol 24:233–234

    Article  Google Scholar 

  19. Setta-Kaffetzi N, Simpson MA, Navarini AA et al (2014) AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 94:790–797

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wilsmann-Theis D, Hagemann T, Dederer H et al (2004) Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1 % ointment. Br J Dermatol 150:1194–1197

    Article  CAS  PubMed  Google Scholar 

  21. Sehgal VN, Verma P, Sharma S et al (2011) Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol 50:1195–1211

    Article  CAS  PubMed  Google Scholar 

  22. Bacharach-Buhles M, el-Gammal S, Altmeyer P (1993) The pustular bacterid (Andrews). Are there clinical criteria for differentiating from psoriasis pustulosa palmaris et plantaris? Hautarzt 44:221–224

    CAS  PubMed  Google Scholar 

  23. Burge SM, Ryan TJ (1985) Acute palmoplantar pustulosis. Br J Dermatol 113:77–83

    Article  CAS  PubMed  Google Scholar 

  24. Hellgren L, Mobacken H (1971) Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol 51:284–288

    CAS  PubMed  Google Scholar 

  25. O’Doherty CJ, MacIntyre C (1985) Palmoplantar pustulosis and smoking. Br Med J (Clin Res Ed) 291:861–864

    Article  Google Scholar 

  26. Enfors W, Molin L (1971) Pustulosis palmaris et plantaris. A follow-up study of a ten-year material. Acta Derm Venereol 51:289–294

    CAS  PubMed  Google Scholar 

  27. Becher G, Jamieson L, Leman J (2015) Palmoplantar pustulosis–a retrospective review of comorbid conditions. J Eur Acad Dermatol Venereol 29:1854–1856

    Article  CAS  PubMed  Google Scholar 

  28. Brunasso AM, Puntoni M, Aberer W et al (2013) Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol 168:1243–1251

    Article  CAS  PubMed  Google Scholar 

  29. Farley E, Masrour S, McKey J et al (2009) Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 60:1024–1031

    Article  PubMed  Google Scholar 

  30. Michaelsson G, Kristjansson G, Pihl LI et al (2007) Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 156:659–666

    Article  CAS  PubMed  Google Scholar 

  31. Benhamou CL, Chamot AM, Kahn MF (1988) Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 6:109–112

    CAS  PubMed  Google Scholar 

  32. Nguyen MT, Borchers A, Selmi C et al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254–265

    Article  PubMed  Google Scholar 

  33. Yamamoto T (2011) Triggering role of focal infection in the induction of extra-palmoplantar lesions and pustulotic arthro-osteitis associated with palmoplantar pustulosis. Adv Otorhinolaryngol 72:89–92

    PubMed  Google Scholar 

  34. Weisenseel P, Kuznetsov AV, Ruzicka T et al (2007) Palmoplantar pustulosis is not inevitably associated with antigliadin antibodies. Br J Dermatol 156:1399–1400

    Article  CAS  PubMed  Google Scholar 

  35. Agner T, Sindrup JH, Hoier-Madsen M et al (1989) Thyroid disease in pustulosis palmoplantaris. Br J Dermatol 121:487–491

    Article  CAS  PubMed  Google Scholar 

  36. Eriksson MO, Hagforsen E, Lundin IP et al (1998) Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 138:390–398

    Article  CAS  PubMed  Google Scholar 

  37. Murakami M, Ohtake T, Horibe Y et al (2010) Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. J Invest Dermatol 130:2010–2016

    Article  CAS  PubMed  Google Scholar 

  38. Uehara M, Ofuji S (1974) The morphogenesis of pustulosis palmaris et plantaris. Arch Dermatol 109:518–520

    Article  CAS  PubMed  Google Scholar 

  39. Murakami M, Hagforsen E, Morhenn V et al (2011) Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 20:845–847

    Article  CAS  PubMed  Google Scholar 

  40. Murakami M, Kaneko T, Nakatsuji T et al (2014) Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. PLoS ONE 9:e110677

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hagforsen E, Edvinsson M, Nordlind K et al (2002) Expression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol 146:383–391

    Article  CAS  PubMed  Google Scholar 

  42. Yoshizaki T, Bandoh N, Ueda S et al (2009) Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. Clin Exp Immunol 157:71–82

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ueda S, Takahara M, Tohtani T et al (2010) Up-regulation of ss1 integrin on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis Palmaris et Plantaris. J Clin Immunol 30:861–871

    Article  PubMed  Google Scholar 

  44. Asumalahti K, Ameen M, Suomela S et al (2003) Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120:627–632

    Article  CAS  PubMed  Google Scholar 

  45. Setta-Kaffetzi N, Navarini AA, Patel VM et al (2013) Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 133:1366–1369

    Article  CAS  PubMed  Google Scholar 

  46. Mossner R, Frambach Y, Wilsmann-Theis D et al (2015) Palmoplantar pustular psoriasis is associated with Missense variants in CARD14, but not with loss-of-function mutations in IL36RN in european patients. J Invest Dermatol 135:2538–2541

    Article  PubMed  Google Scholar 

  47. Kingo K, Mossner R, Koks S et al (2007) Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol 156:646–652

    Article  CAS  PubMed  Google Scholar 

  48. Wu W, Debbaneh M, Moslehi H et al (2014) Tonsillectomy as a treatment for psoriasis: a review. J Dermatolog Treat 25:482–486

    Article  PubMed  Google Scholar 

  49. Kragballe K, Larsen FG (1991) A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol 71:540–542

    CAS  PubMed  Google Scholar 

  50. Marsland AM, Griffiths CE (2001) Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett 6:3–5

    CAS  PubMed  Google Scholar 

  51. Umezawa Y, Nakagawa H, Tamaki K (2015) Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol 43:288

    Article  PubMed  Google Scholar 

  52. Muro M, Kawakami H, Matsumoto Y et al (2015) Topical combination therapy with vitamin D and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study. J Dermatolog Treat 27:51

    Article  PubMed  Google Scholar 

  53. Sevrain M, Richard MA, Barnetche T et al (2014) Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 28(Suppl 5):13–16

    Article  CAS  PubMed  Google Scholar 

  54. Layton AM, Sheehan-Dare R, Cunliffe WJ (1991) A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 124:581–584

    Article  CAS  PubMed  Google Scholar 

  55. Marsland AM, Chalmers RJ, Hollis S et al (2006) Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev CD001433: doi:/10.1002/14651858.cd001433.pub2

    PubMed  Google Scholar 

  56. Lassus A, Geiger JM (1988) Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 119:755–759

    Article  CAS  PubMed  Google Scholar 

  57. Wilken R, Sharma A, Patel F et al (2015) Successful treatment of palmoplantar pustulosis with isotretinoin. Dermatol Online J 21

  58. Reich K, Graff O, Mehta N (2016) Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomised Phase II study. Br J Dermatol : doi:10.1111/bjd.14401

    Google Scholar 

  59. Irla N, Navarini AA, Yawalkar N (2012) Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 167:1170–1174

    Article  CAS  PubMed  Google Scholar 

  60. Adisen E, Tekin O, Gulekon A et al (2009) A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol 23:814–819

    Article  CAS  PubMed  Google Scholar 

  61. Stanford CW, Kollipara R, Melookaran AM et al (2014) Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis 94:153–155

    PubMed  Google Scholar 

  62. Reitamo S, Erkko P, Remitz A et al (1993) Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study. Arch Dermatol 129:1273–1279

    Article  CAS  PubMed  Google Scholar 

  63. Erkko P, Granlund H, Remitz A et al (1998) Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 139:997–1004

    Article  CAS  PubMed  Google Scholar 

  64. Stander H, Stadelmann A, Luger T et al (2003) Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris. Br J Dermatol 149:220–222

    Article  CAS  PubMed  Google Scholar 

  65. Bissonnette R, Nigen S, Langley RG et al (2014) Increased expression of IL-17 A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 28:1298–1305

    Article  CAS  PubMed  Google Scholar 

  66. Robinson A, Van Voorhees AS, Hsu S et al (2012) Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 67:279–288

    Article  CAS  PubMed  Google Scholar 

  67. Bissonnette R, Poulin Y, Bolduc C et al (2008) Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 7:940–946

    CAS  PubMed  Google Scholar 

  68. Au SC, Goldminz AM, Kim N et al (2013) Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat 24:179–187

    Article  CAS  PubMed  Google Scholar 

  69. Tillack C, Ehmann LM, Friedrich M et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17 A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63:567–577

    Article  CAS  PubMed  Google Scholar 

  70. Perez-Zafrilla B, Angel DM, Carmona L (2008) Adverse reactions related to the administration of TNF inhibitors. analysis of a registry of biologic therapy. Reumatol Clin 4:90–95

    Article  PubMed  Google Scholar 

  71. Navarro R, Dauden E (2014) Clinical management of paradoxical psoriasiform reactions during TNF- alpha therapy. Actas Dermosifiliogr 105:752–761

    Article  CAS  PubMed  Google Scholar 

  72. Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233–240

    Article  CAS  PubMed  Google Scholar 

  73. Shmidt E, Wetter DA, Ferguson SB et al (2012) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67:e179–e185

    Article  PubMed  Google Scholar 

  74. Palucka AK, Blanck JP, Bennett L et al (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102:3372–3377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Nestle FO, Conrad C, Tun-Kyi A et al (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202:135–143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Friedrich M, Tillack C, Wollenberg A et al (2014) IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17 C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis 20:1891–1901

    Article  PubMed  Google Scholar 

  77. Denadai R, Teixeira FV, Steinwurz F et al (2013) Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 7:517–524

    Article  PubMed  Google Scholar 

  78. Gregoriou S, Kazakos C, Christofidou E et al (2011) Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 21:104–105

    PubMed  Google Scholar 

  79. Wenk KS, Claros JM, Ehrlich A (2012) Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat 23:212–214

    Article  CAS  PubMed  Google Scholar 

  80. Hay RA, Pan JY (2014) Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 39:751–752

    Article  CAS  PubMed  Google Scholar 

  81. Laino L, DiCarlo A (2011) Palmoplantar pustular psoriasis: clinical and video thermographic evaluation before and after topical tacrolimus treatment. Arch Dermatol 147:760

    Article  PubMed  Google Scholar 

  82. Hayama K, Inadomi T, Fujisawa D et al (2010) A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol 20:758–762

    CAS  PubMed  Google Scholar 

  83. Wozel G, Vitez L (2008) Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol 88:169–170

    Article  PubMed  Google Scholar 

  84. Morales-Munera C, Vilarrasa E, Puig L (2013) Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 168:820–824

    Article  CAS  PubMed  Google Scholar 

  85. Gerdes S, Franke J, Domm S et al (2010) Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 163:1116–1118

    Article  CAS  PubMed  Google Scholar 

  86. Bertelsen T, Kragballe K, Johansen C et al (2014) Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 53:e464–e466

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SCIderm Clinical Research and Dermatologikum, Hamburg, Deutschland

    P. Weisenseel, C. Kahl & K. Reich

  2. Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, Bonn, Deutschland

    D. Wilsmann-Theis

  3. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, UMG, 37075, Göttingen, Deutschland

    K. Reich &  R. Mössner

Authors
  1. P. Weisenseel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Wilsmann-Theis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Kahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Mössner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Mössner.

Ethics declarations

Interessenkonflikt

P. Weisenseel hat von folgenden Firmen unregelmäßig Honorare und/oder Reisekosten für Berater- und/oder Vortragstätigkeiten erhalten und/oder war an klinischen Studien der folgenden Firmen beteiligt: Abbott/Abbvie, Biogen Idec, Dexcel, Eli Lilly, Galderma, GSK, Janssen-Cilag, Leo Pharma, Medac, MSD (früher Essex), Novartis, Pfizer (früher Wyeth). D. Wilsmann-Theis erhielt Vergütung von Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten oder Reisekostenunterstützung in alphabetischer Reihenfolge von den Firmen Abbvie, Almirall Hermal, Amgen, Biogen IDEC, Celgene, Janssen-Cilag, Leo Pharma, Lilly, Merck Serono, MSD Sharp & Dohme, Novartis Pharma und Pfizer. C. Kahl gibt an, dass kein Interessenkonflikt besteht. K. Reich fungierte als Berater und/oder bezahlter Redner und/oder nahm an klinischen Studien teil, die gesponsert wurden von Abbvie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer, Regeneron, Takeda, UCB Pharma, Xenoport. R. Mössner erhielt Vergütung von Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten oder Reisekostenunterstützung in alphabetischer Reihenfolge von den Firmen Abbvie, Biogen IDEC, Celgene, Janssen-Cilag, Leo Pharma, Lilly, Merck Serono, MSD Sharp & Dohme, Novartis Pharma und Pfizer.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

P. Weisenseel und D. Wilsmann-Theis teilen sich die Erstautorenschaft.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weisenseel, P., Wilsmann-Theis, D., Kahl, C. et al. Pustulöse Psoriasis. Hautarzt 67, 445–453 (2016). https://doi.org/10.1007/s00105-016-3804-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-016-3804-4

Schlüsselwörter

Keywords

Search

Navigation